Details
| Translated title of the contribution | The perspective of the private health insurance in Germany for health economic evaluations: Sense and realization |
|---|---|
| Original language | German |
| Pages (from-to) | 185-191 |
| Number of pages | 7 |
| Journal | Gesundheitsokonomie und Qualitatsmanagement |
| Volume | 17 |
| Issue number | 4 |
| Early online date | 5 Jan 2012 |
| Publication status | Published - Aug 2012 |
Abstract
At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Gesundheitsokonomie und Qualitatsmanagement, Vol. 17, No. 4, 08.2012, p. 185-191.
Research output: Contribution to journal › Review article › Research › peer review
}
TY - JOUR
T1 - Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen
T2 - Sinnhaftigkeit und Umsetzung
AU - Lange, A.
AU - Prenzler, A.
AU - Graf Von Der Schulenburg, J. M.
PY - 2012/8
Y1 - 2012/8
N2 - At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.
AB - At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.
KW - cost analyses
KW - costs
KW - Germany
KW - methods
KW - perspective
KW - Private Health Insurance
UR - http://www.scopus.com/inward/record.url?scp=84865468149&partnerID=8YFLogxK
U2 - 10.1055/s-0031-1282020
DO - 10.1055/s-0031-1282020
M3 - Übersichtsarbeit
AN - SCOPUS:84865468149
VL - 17
SP - 185
EP - 191
JO - Gesundheitsokonomie und Qualitatsmanagement
JF - Gesundheitsokonomie und Qualitatsmanagement
SN - 1432-2625
IS - 4
ER -